How these names differ, why CJC-1295 DAC data cannot be transferred to a no-DAC listing, and what to check in a blended research material.
Ipamorelin, CJC-1295 and Sermorelin appear together in discussions of growth-hormone-related research, but a shared research context does not make them interchangeable. Their sequences, modifications and receptor relationships must be kept separate when interpreting a paper or a product record.
Sermorelin denotes the amidated GHRH/GRF 1–29 fragment, as recorded in the FDA substance identity database. Ipamorelin is a structurally distinct pentapeptide secretagogue. CJC-1295 terminology needs additional care because catalogue descriptions sometimes use “no DAC” for modified GRF 1–29, while the original long-acting CJC-1295 literature concerns an albumin-binding modification.
Raun and colleagues' 1998 Ipamorelin paper describes its structure and pharmacology in experimental systems. It is not a study of a mixed commercial vial.
Jetté and colleagues' 2005 CJC-1295 study describes modified GRF 1–29 derivatives with an albumin-reactive group and work in cell and rat models. That modification is a defining part of the molecule studied. The 2006 study by Teichman and colleagues then examined a long-acting CJC-1295 preparation in healthy adults. Its reported persistence cannot be assigned to a no-DAC catalogue material by shortening the name to “CJC”.
These sources identify particular molecules and preparations. They do not establish outcomes, equivalence or administration guidance for the PCUK listing.
| Name on a record | Detail to establish before comparing it |
|---|---|
| Sermorelin | Exact GHRH fragment and terminal form |
| Ipamorelin | Compound identity, sequence or reference identifier and supplied form |
| CJC-1295 with DAC | Whether the albumin-binding modification is explicitly specified |
| CJC-1295 no DAC | The actual modified GRF identity, without assuming the DAC study preparation |
| CJC/Ipamorelin blend | Both component identities, their labelled amounts and the combined quantity |
Our no-DAC identity guide covers the naming issue in more detail. A certificate that says only “CJC/IPA” needs enough additional context to tie its target definitions to the material supplied.
The CJC-1295 no DAC + Ipamorelin 10mg listing describes a combined research material. Read its component specification and report together. The total quantity is not the quantity of each component, and a blend is not the same procurement format as separate vials.
An analytical report should state which components were identified or quantified and how the results are expressed. A single unexplained percentage cannot answer every composition question. Our HPLC guide and COA guide distinguish those measurements. Use the current product page for availability rather than assuming a standalone compound is stocked because it appears in this comparison.
Materials supplied by this site are solely for non-clinical in-vitro laboratory research, not for use in or on humans or animals. This reference provides no dosing, administration, treatment or in-vivo protocol. Laboratory work requires an appropriate institutional SOP and risk assessment.
What "CJC-1295 no DAC" means, how it differs from the DAC form, and how to check which one a certificate describes.
Research DocumentationHow chromatographic peak-area purity differs from identity, quantity and mass fraction, and which method details matter when reading a peptide report.
Site materials are supplied solely for non-clinical in-vitro laboratory research. They must not be used in or on humans or animals. We do not provide dosing, routes of administration, treatment, cosmetic-use or in-vivo guidance. Read the legal and research-use terms.